Patients with clinical stage IV or inoperable stage III breast cancer are expected to be enrolled in the study. The purpose of the study will be to evaluate the biologic effects on tissue and plasma in patients treated with paclitaxel alone and in combination with Panzem NCD (2-methoxyestradiol or 2ME2). The safety and tolerability of Panzem NCD in combination with weekly paclitaxel will also be evaluated.
The single center study will be conducted at the Duke University Medical Center under a grant from the Susan G Komen Breast Cancer Foundation.
Dr Kimberly Blackwell, director of clinical trials in breast cancer at the Duke University Medical Center, will serve as principal investigator for the study.
“The concept of targeting the angiogenic pathways has already proven successful with commercialized agents in breast cancer. Through this study, we will combine an approved standard-of-care agent, paclitaxel, with an experimental drug candidate, Panzem NCD, with the hope to further support that success,” said Dr Blackwell.